Main Menu

Video: Work with the world’s leading academic centre for drug discovery in oncology

The Institute of Cancer Research is the world’s leading academic centre for drug discovery. ICR scientists have discovered 20 new drug candidates since 2005, of which 11 have entered clinical trials.

The ICR’s Division for Cancer Therapeutics houses around 200 scientists and brings together a wide variety of disciplines, including cell and molecular biology, pharmacology, tumour modelling, computational and structural biology, and medicinal chemistry.

The division works to select promising drug targets, design effective prototype drugs and biomarkers, and develop strategies to counter drug resistance. Its scientists work closely with researchers in drug development across the ICR and with clinical researchers, including in the joint Drug Development Unit (DDU), a flagship partnership between the ICR and its partner hospital The Royal Marsden.

Professor Ian Collins is Head of Chemistry in the Cancer Research UK Cancer Therapeutics Unit at the ICR. He has been involved drug discovery research for 25 years, since starting his career in a major pharmaceutical company.

Professor Collins leads a team of medicinal chemists who are aiming to discover new cancer drugs. Their impressive track record includes the transformation of several hit compounds to potent and selective drug molecules – such as the discovery of AKT and Chk1 kinase inhibitors that led to clinical candidates. His team is currently exploring several new targets.

Professor Collins’ work hugely benefits from collaborating with others – including cancer biologists within the Cancer Therapeutics Unit and industrial partners. These interactions help to generate new ideas and accelerate the discovery and development of new drug candidates with the most potential for treating cancer.


Watch more videos of our researchers

Working with pharmaceutical companies

Dr Marco Gerlinger talking about working with pharmaceutical companies

Dr Marco Gerlinger's Translational Oncogenomics Team are keen to develop new partnerships to continue their work, and to access drugs that could reverse the resistance mechanisms that the team has identified so far.


New partnerships in cancer epigenetics

Professor Jessica Downs

Our Epigenetics and Genome Stability team, led by Professor Jessica Downs, is working on a variety of research programmes that could be developed in collaboration with commercial partners.


Sharing experience with industry partners

Dr Paul Huang

Our Molecular and Systems Oncology Team, led by Dr Paul Huang, is keen to collaborate with industry partners on a number of projects on biochemistry, computational modelling, molecular pathology and proteomics.


Collaborating with commercial partners

Dr Anguraj Sadanandam

Our Systems and Precision Cancer Medicine team, led by Dr Anguraj Sadanandam, is investigating ways to stratify tumours based on their genetic and clinical diversity.


Exploring new opportunities for collaborative working

Professor Uwe Oelfke

Professor Uwe Oelfke, Deputy Head of the Division of Radiotherapy and Imaging, is keen to explore new opportunities for collaborative working with industry.


The benefits of partnering with industry

Dr Igor Vivanco

Our Molecular Addictions team, led by Dr Igor Vivanco, is working on a variety of projects that could be developed in collaboration with commercial partners.


Connections newsletter

Sign up to our new quarterly newsletter for updates on our Business and Innovation Office and news about working with industry.